Q3 FY2026 · ended Jun 30, 2026 · Revenue $271.70M, -8.1% YoY · Filed Aug 7, 2026
Embecta Corp. (EMBC) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In Q3 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $271.7 million and net income of $21.1 million. Free cash flow was $40.7 million. As of Jun 30, 2026 it held $214.7 million in cash and investments and $1.5 billion in total debt.
Revenue
$271.70M
-8.1% vs year-ago quarter
Net income
$21.10M
-53.6% vs year-ago quarter
Operating cash flow
$41.80M
-48.5% vs year-ago quarter
Free cash flow
$40.70M
-49.6% vs year-ago quarter
EPS
$0.36
-53.8% vs year-ago quarter
Dividend per share
$0.01
-93.3% vs year-ago quarter
Shares outstanding
56.66M
-3.1% vs year-ago quarter
Net cash
$-1.29B
Q3 FY2026
Operating margin
21.9%
TTM
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- EMBC (Nasdaq)
- Fiscal year ends
- September 30
- Incorporated in
- DE
- Headquarters
- Parsippany, NJ
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1872789
- Former names
- Berra Newco, Inc. (until Sep 3, 2021)
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Jun 30, 2026 |
Q2 FY2026 Mar 31, 2026 |
Q1 FY2026 Dec 31, 2025 |
Q4 FY2025 Sep 30, 2025 |
Q3 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $271.7M | $221.8M | $261.2M | $264.0M | $295.5M |
| Operating income | $48.7M | $35.0M | $83.3M | $56.5M | $94.0M |
| Net income | $21.1M | -$4.1M | $44.1M | $26.4M | $45.5M |
| Diluted EPS | $0.36 | -$0.07 | $0.74 | $0.44 | $0.78 |
| Operating cash flow | $41.8M | $31.1M | $17.2M | $84.0M | $81.2M |
| Free cash flow | $40.7M | $30.6M | $16.6M | $76.7M | $80.8M |
| Total assets | $1.3B | $1.0B | $1.1B | $1.1B | $1.2B |
| Stockholders' equity | -$612.7M | -$626.1M | -$613.1M | -$650.6M | -$669.6M |
| Cash and investments | $214.7M | $184.9M | $201.3M | $225.5M | $230.6M |
| Total debt | $1.5B | $1.4B | $1.4B | $1.4B | $1.5B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 7, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 7, 2026 | Aug 7, 2026 |
| 8-K/A | Amended current report | Jul 31, 2026 | May 15, 2026 |
| 8-K |
Current report
Acquisition or sale of assets, Regulation FD disclosure
|
May 15, 2026 | May 15, 2026 |
| 10-Q | Quarterly report | May 5, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 5, 2026 | May 5, 2026 |
All 262 Embecta Corp. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.